1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
−Removed: As disclosed in the table below, during the first quarter of 2024, certain directors adopted a “Rule 10b5-1 trading arrangement”.
−Removed: These plans provide for the sale of our common stock and are intended to satisfy the affirmative defense in Rule 10b5-1(c).
−Removed: Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (1)
−Removed: Maximum Total Shares of Common Stock to be Sold Under the Plan (2)
−Removed: 3/21/2024 7/1/2025 30,720
−Removed: Jennifer Cook
−Removed: 3/1/2024 6/3/2025 1,458
−Removed: __________________________________________________
−Removed: (1) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.
−Removed: (2) This amount represents the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements.
−Removed: No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the first quarter ended March 31, 2024.
+Added: No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2024.
+Added: Entry into a Material Definitive Agreement
+Added: On July 26, 2024, Denali and Biogen MA, Inc.
+Added: and Biogen International GMBH (collectively, “Biogen”) executed a Side Letter to the Right of First Negotiation, Option and License Agreement (the “ROFN and Option Agreement”), entered into on October 6, 2020 and amended on August 17, 2023.
+Added: Pursuant to the Side Letter, Biogen terminated its license to the ATV:Abeta program enabled by Denali’s TfR-targeting technology against amyloid beta for the potential treatment of Alzheimer's disease, effective as of the date of the Side Letter, and granted Denali rights to data generated during the collaboration.
+Added: As a result of the termination, all rights to develop, manufacture, perform medical affairs activities, and commercialize new TfR-targeting ATV:Abeta therapeutics reverted to Denali.
+Added: The foregoing description of the Side Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Side Letter, which is filed as an exhibit hereto.
EXHIBIT INDEX
2 unchanged sentences
Number Filing Date
−Removed: Form of P re- F und ed W arrant
+Added: Denali - Biogen Side Letter.
— — — Filed herewith
18 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2024, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
4 unchanged sentences
DENALI THERAPEUTICS INC.
−Removed: May 7, 2024 By:
+Added: August 1, 2024 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 7, 2024 By:
+Added: August 1, 2024 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.